Therapeutic management of premenstrual syndrome

被引:24
作者
Freeman, Ellen W. [1 ,2 ]
机构
[1] Univ Penn, Dept Obstet Gynecol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
关键词
menstrual disorders; oral contraceptives; PMS; premenstrual syndrome; serotonin reuptake inhibitors; treatment; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; DYSPHORIC DISORDER; LUTEAL-PHASE; ORAL-CONTRACEPTIVES; HYPERICUM-PERFORATUM; SERTRALINE TREATMENT; AGNUS CASTUS; EFFICACY; FLUOXETINE;
D O I
10.1517/14656566.2010.509344
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Premenstrual syndrome (PMS) is among the most common health problems reported by reproductive-age women. Estimates indicate that up to 25% of women may warrant treatment for the distress or impaired functioning associated with the symptoms. Areas covered in this review: The primary focus of this review is the clinical condition of PMS and randomized, placebo-controlled trials of PMS treatment. A literature search in PubMed was conducted for these topics. The most recent reports of specific treatments in controlled treatment studies and all meta-analyses were selected. What the reader will gain: Reports consistently indicate that serotonergic antidepressants reduce PMS symptoms compared to a placebo. Hormonal treatments are the most widely prescribed medical treatment. Some oral contraceptives and gonadotropin-releasing hormone analogs have demonstrated efficacy, particularly for women who want contraception and PMS symptom control. Numerous non-pharmacologic treatments are utilized, but efficacy is reported only for calcium supplements, Vitex agnus castus (chasteberry), and cognitive-behavioral therapies. Further research to develop new therapies for the 40% of women with PMS who do not respond to the currently available treatments is needed. Take home message: There are treatments with demonstrated efficacy for PMS, and the majority of women can be helped.
引用
收藏
页码:2879 / 2889
页数:11
相关论文
共 106 条
[21]   Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo-controlled, clinical trial using computerized diaries [J].
Cohen, LS ;
Miner, C ;
Brown, E ;
Freeman, EW ;
Halbreich, U ;
Sundell, K ;
McCray, S .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) :435-444
[22]   A SURVEY OF 658 WOMEN WHO REPORT SYMPTOMS OF PREMENSTRUAL-SYNDROME [J].
CORNEY, RH ;
STANTON, R .
JOURNAL OF PSYCHOSOMATIC RESEARCH, 1991, 35 (4-5) :471-482
[23]   Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome [J].
Cronje, WH ;
Vashisht, A ;
Studd, JWW .
HUMAN REPRODUCTION, 2004, 19 (09) :2152-2155
[24]   Exercise and Premenstrual Symptomatology: A Comprehensive Review [J].
Daley, Amanda .
JOURNAL OF WOMENS HEALTH, 2009, 18 (06) :895-899
[25]  
DENNERSTEIN L, 1986, HORM BEHAV, P175
[26]   Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome [J].
Di Carlo, C ;
Palomba, S ;
Tommaselli, GA ;
Guida, M ;
Sardo, AD ;
Nappi, C .
FERTILITY AND STERILITY, 2001, 75 (02) :380-384
[27]   OPEN TRIAL OF FLUOXETINE THERAPY FOR PREMENSTRUAL-SYNDROME [J].
ELKS, ML .
SOUTHERN MEDICAL JOURNAL, 1993, 86 (05) :503-507
[28]  
ERIKSSON E, 1995, NEUROPSYCHOPHARMACOL, V12, P167, DOI 10.1016/0893-133X(94)00076-C
[29]   Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder [J].
Eriksson, Elias ;
Ekman, Agneta ;
Sinclair, Suzanne ;
Sorvik, Karin ;
Ysander, Christina ;
Mattson, Ulla-Britt ;
Nissbrandt, Hans .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (02) :195-202
[30]   Added benefits of drospirenone for compliance [J].
Foidart, JM .
CLIMACTERIC, 2005, 8 :28-34